您的账号已在其他设备登录,您当前账号已强迫下线,
如非您本人操作,建议您在会员中心进行密码修改

确定
收藏 | 浏览213

Renal angiomyolipoma (AML) and perivascular epithelioid cell tumor (PEComa) are members of the microphthalmia-associated transcription factor (MiTF) family of tumors. Traditionally, HMB45 and MelanA have been used to diagnose these lesions; however, low sensitivity can render interpretation difficult. PNL2 is a sensitive and specific biomarker for epithelioid melanoma, and immunoreactivity has also been shown in small series of PEComas. This study determined the utility of PNL2 in MiTF and non-MiTF renal tumors.PNL2 immunostaining was performed on 196 tumors, including 40 MiTF renal tumors (AMLs, epithelioid AMLs, sclerosing PEComas, malignant PEComas, and Xp11.2 renal cell carcinomas (RCCs)) and 156 non-MiTF renal tumors. HMB45, MelanA and CathepsinK were also evaluated in a subset of MiTF tumors. Overall, 85

作者:Previn, Gulavita;Christopher D M, Fletcher;Michelle S, Hirsch

来源:Histopathology 2017 年

知识库介绍

临床诊疗知识库该平台旨在解决临床医护人员在学习、工作中对医学信息的需求,方便快速、便捷的获取实用的医学信息,辅助临床决策参考。该库包含疾病、药品、检查、指南规范、病例文献及循证文献等多种丰富权威的临床资源。

详细介绍
热门关注
免责声明:本知识库提供的有关内容等信息仅供学习参考,不代替医生的诊断和医嘱。

收藏
| 浏览:213
作者:
Previn, Gulavita;Christopher D M, Fletcher;Michelle S, Hirsch
来源:
Histopathology 2017 年
标签:
Cathepsin K HMB45 MelanA MiTF PEComa PNL2 angiomyolipoma immunohistochemistry translocation renal cell carcinoma
Renal angiomyolipoma (AML) and perivascular epithelioid cell tumor (PEComa) are members of the microphthalmia-associated transcription factor (MiTF) family of tumors. Traditionally, HMB45 and MelanA have been used to diagnose these lesions; however, low sensitivity can render interpretation difficult. PNL2 is a sensitive and specific biomarker for epithelioid melanoma, and immunoreactivity has also been shown in small series of PEComas. This study determined the utility of PNL2 in MiTF and non-MiTF renal tumors.PNL2 immunostaining was performed on 196 tumors, including 40 MiTF renal tumors (AMLs, epithelioid AMLs, sclerosing PEComas, malignant PEComas, and Xp11.2 renal cell carcinomas (RCCs)) and 156 non-MiTF renal tumors. HMB45, MelanA and CathepsinK were also evaluated in a subset of MiTF tumors. Overall, 85